CEL-SCI CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
CEL-SCI CORPORATION (CVM) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.51% for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-29.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2025-12-29
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.51%, a 1.53% decline from fiscal 2024.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.58%, a 7.76% increase from fiscal 2023.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.25%, a 23.91% increase from fiscal 2022.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.43%, a 107.88% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 24 month |
|---|---|---|
| 2025-09-30 | 4.51% 10-K · filed 2025-12-29 | |
| 2024-09-30 | 4.58% 10-K · filed 2025-12-29 | |
| 2023-09-30 | 4.25% 10-K · filed 2025-01-13 | |
| 2022-09-30 | 3.43% 10-K · filed 2023-12-21 | |
| 2021-09-30 | 1.65% 10-K · filed 2021-12-21 | 1.65% 10-K · filed 2022-12-27 |
| 2020-09-30 | 1.87% 10-K · filed 2021-12-21 | |
| 2019-09-30 | 2.82% 10-K · filed 2020-12-29 | |
| 2018-09-30 | 3.04% 10-K/A · filed 2019-12-23 | |
| 2017-09-30 | 2.29% 10-K · filed 2018-12-19 | |
| 2016-09-30 | 1.06% 10-K · filed 2017-12-29 | |
| 2015-09-30 | 2.35% 10-K/A · filed 2017-12-11 | |
| 2014-09-30 | 2.65% 10-K/A · filed 2017-12-11 | |
| 2013-09-30 | 2.73% 10-K · filed 2015-12-11 | |
| 2012-09-30 | 1.92% 10-K · filed 2014-12-23 | |
| 2011-09-30 | 3.68% 10-K · filed 2013-12-27 | |
| 2010-09-30 | 4.01% 10-K · filed 2012-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |